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For the purpose of comparing the efﬁcacy and safety of a Similar Biotherapeutic Product (SBP) to
a Reference Biotherapeutic Product (RBP), the “Guidelines on Evaluation of Similar Biotherapeutic
Products (SBPs)” issued by the World Health Organisation (WHO), states that equivalence or non-
inferiority studies may be acceptable. While in principle, equivalence trials are preferred, non-
inferiority trials may be considered if appropriately justiﬁed, such as for a medicinal product with
a wide safety margin. However, the statistical issues involved in the design, conduct, analysis and
interpretation of equivalence and non-inferiority trials are complex and subtle, and require that all
aspects of these trials be given careful consideration. These issues are important in order to ensure that
equivalence and non-inferiority trials provide valid data that are necessary to draw reliable conclusions
regarding the clinical similarity of an SBP to an RBP.
Crown Copyright  2011 Published by Elsevier Ltd. Open access under CC BY-NC-ND license.1. Introduction
According to the guidelines developed by the WHO for the
evaluation of SBPs, clinical trials utilising equivalence or non-
inferiority designs will be acceptable for the comparison of efﬁ-
cacy and safety of the SBP to the RBP [1]. Equivalence trials are
preferred to ensure that the SBP is not clinically less or more
effective than the RBP when used at the same dosage(s), but non-
inferiority trials may be considered, if appropriately justiﬁed [1,2].
The choice of the clinical trial design is dependent on many factors,
and the speciﬁc design selected for a particular study must be
explicitly stated in the trial protocol. Specifying the design selected
is critical, given that equivalence and non-inferiority trials are
designed to test different objectives. In addition, it should also be
recognised that the statistical principles governing equivalence
and non-inferiority trials are complex and subtle, and must be
given careful consideration [3]. This article will address the
statistical principles underlying equivalence and non-inferiority
trials that must be considered in the design, conduct, analysis
and interpretation of trials for the purpose of demonstrating that
the SBP is similar to the RBP.evier Ltd. Open access under CC BY-N2. Equivalence vs. non-inferiority, and the choice of the
comparability margin
An equivalence trial is designed to show that a test treatment
differs from the standard active treatment by an amount that is
clinically unimportant (the equivalence margin), while a non-
inferiority trial is designed to show that a test treatment is not
less effective than a standard active treatment by a small pre-
deﬁned margin (the non-inferiority margin) [4]. These are
different objectives, and it is vital that the speciﬁc design selected
for a particular study be explicitly stated in the trial protocol [5].
The factors that should be considered in selecting the clinical trial
design include: the product in question, the intended use of the
product, the target population and disease prevalence [1].
Irrespective of the trial design selected, the next critical step is
the determination of the comparability margin. For the equivalence
trial, both the upper and lower equivalence limits are needed to
establish that the SBP response differs from the RBP response by
a clinically unimportant amount. For a non-inferiority trial, only
one limit is required to establish that the SBP response is not
clinically inferior to the RBP response by a pre-speciﬁed margin [6].
Determination of this margin must be given careful consideration
as both sample size calculations and interpretation of study results
depend on it. In practical terms, the comparability margin is
deﬁned as the largest difference between the SBP and the RBP that
can be judged as clinically acceptable, and should be smaller thanC-ND license.
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the margin is based upon a combination of clinical judgement and
statistical reasoning to deal with uncertainties and imperfect
information. Adequate evidence of the effect size of the RBP should
be provided to support the proposed margin. The magnitude and
variability of the effect size of the RBP derived from historical trials
should also be taken into consideration.
3. Sample size and power
It is important to note that equivalence and non-inferiority
designs test different hypotheses requiring different formulae for
power and sample size calculations [4]. For an equivalence trial, the
null hypothesis represents lack of equivalence between the test and
reference while for an non-inferiority trial, it represents inferiority
of the test to the reference. Therefore, sample size calculations
should be based on methods speciﬁcally designed for either
equivalence or non-inferiority trials. Details of the sample size
calculations should be provided in the study protocol. At
a minimum, the basis of estimates of any quantities used in the
sample size calculation should also be clearly explained, and are
usually derived from results of earlier trials with the RBP or pub-
lished literature [6].
Determination of the appropriate sample size is dependent on
various factors including: the type of primary endpoint (e.g. binary,
quantitative, time-to event etc.), the pre-deﬁned comparability
margin, the probability of a type I error (falsely rejecting the null
hypothesis) and the probability of a type II error (erroneously
failing to reject the null hypothesis) [4,6]. The expected rates of
patient dropouts and withdrawals should also be taken into
consideration. Keeping all factors the same, including the compa-
rability margin, the type I error rate and the type II error rate, an
equivalence trial tends to need a larger sample size than a non-
inferiority trial. When estimating the sample size for equivalence
or non-inferiority trials, it is usually under the assumption that
there is no difference between the SBP and RBP. An equivalence trial
could be underpowered if the true difference is not zero. Similarly,
a non-inferiority trial could be underpowered if the SBP is actually
less effective than the RBP. To minimise the risk of an underpow-
ered study, the equivalence or non-inferiority trial should only be
considered and designed once similarity of the SBP to the RBP has
been ascertained using all available comparative data that has been
generated between the SBP and the RBP [1]. In addition, keeping
the probability of a type II error low by increasing the study power
will increase the ability of the study to show equivalence or non-
inferiority of the SBP to the RBP.
4. Important principles: assay sensitivity and the constancy
assumption
Potential differences between the SBP and the RBP should be
investigated in a sensitive and well established clinical model [1,2].
The sensitivity of the clinical model is important, and there should
be some conﬁdence in the trial’s ability to detect a difference
between the SBP and the RBP if a real difference exists. This is the
concept of assay sensitivity, and refers to the ability of a speciﬁc
trial to demonstrate a difference between treatments if such
a difference truly exists [7].
Assay sensitivity is crucial to any trial, but has different impli-
cations depending on the trial design. A superiority trial that lacks
assay sensitivity will fail to show superiority of the test treatment (a
failed study), and a superiority trial that demonstrates superiority
has simultaneously demonstrated assay sensitivity. However,
a non-inferiority or equivalence trial that lacks assay sensitivity
may ﬁnd an ineffective treatment to be non-inferior or equivalentand could lead to an erroneous conclusion of efﬁcacy [4]. The effect
size of the RBP in the current non-inferiority or equivalence trial is
not measured directly relative to placebo, and assay sensitivity
must be deduced. In fact, the current non-inferiority or equivalence
trial must rely on the assumption of assay sensitivity based on
information external to the trial. Factors which can reduce assay
sensitivity include poor compliance with study medication,
concomitant medications, missing data, patient withdrawals, vari-
ability in measurements, poor trial quality etc. The design and
conduct of the non-inferiority or equivalence trial must attempt to
avoid or at least minimise these factors to ensure the credibility of
trial results.
Another important principle in equivalence and non-inferiority
trials is the constancy assumption, which means that the historical
active control effect size compared to placebo is unchanged in the
setting of the current trial [7]. To ensure the validity of the
constancy assumption, the equivalence or non-inferiority trial must
be designed and conducted in the same manner as the trial that
established the efﬁcacy of the RBP. The study population,
concomitant therapy, endpoints, trial duration, assessments and
other important aspects of the trial should be similar to those in the
trial used to demonstrate the effectiveness of the RBP.
Trial conduct should not only adhere closely to that of the trial
used to demonstrate the effectiveness of the RBP, but it should also
be conducted with high quality to ensure assay sensitivity.
5. Data analysis and analysis populations
Data analysis from equivalence and non-inferiority studies is
generally based on the use of two-sided conﬁdence intervals
(typically at the 95% level) for the metric of treatment effect.
Examples of metrics of treatment effect include absolute difference
in proportions, relative risk, odds ratio and hazard ratio. Analysis of
non-inferiority trials can also be based on a one sided conﬁdence
interval (typically at the 97.5% level) [6]. For equivalence trials,
equivalence is demonstrated when the entire conﬁdence interval
falls within the lower and upper equivalence limits. Non-inferiority
trials are one sided, and statistical inference is based only on the
upper or lower conﬁdence limit, whichever is appropriate for
a given study [8]. For example, if a lower non-inferiority margin is
deﬁned, non-inferiority is demonstrated when the lower limit of
the conﬁdence interval is above this margin. Likewise, if an upper
non-inferiority margin is deﬁned, non-inferiority is demonstrated
when the upper limit of the conﬁdence interval is below this
margin.
In a superiority trial, analysis based on the Intent to Treat (ITT)
population is considered the primary analysis, and is considered
conservative in this setting. However, for equivalence and non-
inferiority trials, the ITT population is not considered conserva-
tive as it tends to bias the results towards equivalence or non-
inferiority. The per-protocol (PP) population excludes data from
patients with major protocol violations, and excluding data from
these patients can also substantially bias the results, especially if
a large proportion of subjects are excluded. Hence, a conservative
analysis cannot always be deﬁned for equivalence or non-
inferiority trials, and this will present challenges during the anal-
ysis of the trial results [9]. Equivalence or non-inferiority trials
should be analysed based on both the ITT and PP approaches, and
both sets of results should support the conclusion of equivalence or
non-inferiority.
6. Trial results: possible outcomes and interpretation
Irrespective of the trial design, the totality of the actual observed
results obtained from the clinical trial will determine whether the
C. Njue / Biologicals 39 (2011) 266e269268SBP and the RBP can be considered clinically similar. Fig. 1 shows
the possible results (conﬁdence intervals) from a non-inferiority or
equivalence trial designed to compare a test to a reference for
which a higher value in the endpoint corresponds to better efﬁcacy,
and the difference between treatments is deﬁned as test minus
reference.
As illustrated in Fig. 1 where the lower limit of the equivalence
region also represents the non-inferioritymargin, several outcomes
can be obtained from the analysis based on the conﬁdence interval
approach. The following is an interpretation of each outcome:
1. Trial failed, regardless of objective (Test is worse than
Reference);
2. Trial failed, regardless of objective (Test is not better, but could
be worse than Reference);
3. Trial failed, regardless of objective (Trial is completely non-
informative: Test could be worse than or better than
Reference);
4. Test equivalent and therefore, also non-inferior to Reference
(entire conﬁdence interval within equivalence region);
5. Test not equivalent but non-inferior to Reference (lower limit of
conﬁdence interval above non-inferiority margin);
6. Test not equivalent but statistically and clinically superior to
Reference (lower limit of conﬁdence interval above equivalence
region).
For comparing the SBP to the RBP, outcome 4 is the most
desirable, but as illustrated by the simulation study described
below, such an outcome can only be obtained from an adequately
powered equivalence trial, and would be unlikely to be obtained
from a trial that was designed as a non-inferiority study.
Outcome 5 has different implications for a non-inferiority trial
compared to an equivalence trial, resulting in a successful non-
inferiority trial, but a failed equivalence trial. Outcome 6 would
result in a failed equivalence trial, but would be acceptable in
a non-inferiority trial if it does not matter whether the test treat-
ment can yield a much better response than the reference [4].
However, in the context of comparing the SBP to the RBP for the
purpose of demonstrating that the SBP is not clinically less or more
effective than the RBP when used at the same dosage(s), outcome 6
is not desirable as it suggests superiority of the SBP relative to the
RBP. As stated in the WHO guidance document, such a ﬁnding, if
clinically relevant, would contradict the principle of similarity and
a post-hoc justiﬁcation that a ﬁnding of statistical superiority is not
clinically relevant would be difﬁcult to defend [1]. If similarity of
the SBP to the RBP has been ascertained prior to initiation of the
conﬁrmatory trial, outcome 6 is expected to be a rare event. This1
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Fig. 1. Possible results (conﬁdence intervals) from a non-inferiority or equivalence
trial.was revealed in the simulation study described below where the
proportion of simulated conﬁdence intervals showing statistical
superiority was about 2%.
If the statistical superiority observed is considered clinically
relevant, then the SBP would not be considered similar to the RBP
and should be developed as a stand alone product [1,2]. This is
clearly an undesirable ﬁnding at the end of a conﬁrmatory trial that
marks the end of the comparability exercise [1]. Demonstration
that superior efﬁcacy of the SBP is not associated with adverse
events, if the SBP is prescribed at the same dosage as the RBP would
also be required in all cases [1,2]. To minimise the risk of a superi-
ority ﬁnding, all comparative data that have been generated
between the SBP and the RBP should be carefully reviewed and
analysed to ensure that similarity between the SBP and the RBP has
been establishedwith a high degree of conﬁdence prior to initiating
the conﬁrmatory trial [1].7. A simulation study
A direct simulation of 95% conﬁdence intervals for differences in
proportions was carried out. Each simulationwas set up to generate
data from a non-inferiority study with a binary primary endpoint
under the assumption that the proportions in the test and reference
groups are equal. The goal of the simulation study was to demon-
strate that equivalence trials require more subjects than non-
inferiority trials, and that an adequately powered equivalence
trial is needed to obtain outcome 4 (test equivalent to reference).
Two independent binomial samples of given sample sizes and
underlying proportions of success were generated, and the
approximate 95% two-sided conﬁdence interval for the difference
in proportions (test proportion minus reference proportion) was
calculated for each simulation. A range of proportions was
considered, and both proportions were set equal. With the non-
inferiority margin set to 10%, the simulations were carried out
10,000 times, with the number of subjects in each treatment group
selected in order for each simulated study to have a speciﬁed
power. From all the simulations, the observed frequency of conﬁ-
dence intervals supporting claims of non-inferiority (test propor-
tion at most 10% lower) and the observed frequency of conﬁdence
intervals supporting claims of equivalence (entire conﬁdence
interval within the equivalence region) were calculated.
The simulation results are summarised in Table 1. The results in
Table 1 illustrate that outcome 4 (Test equivalent to Reference:
entire conﬁdence interval within equivalence region) can be difﬁ-
cult to obtain from a trial designed as a non-inferiority study, and
show that the proportion of simulated conﬁdence intervals sup-
porting claims of equivalence is about 20% lower (for 80% power)
and about 10% lower (for 90% power) compared to the proportion of
simulated conﬁdence intervals supporting claims of non-Table 1
Proportion of simulated conﬁdence intervals supporting claims of non-inferiority or
equivalence of test to reference.
Power Proportion
of success
(p1 ¼ p2)
Required
number of
subjects
(N1 ¼ N2)
Proportion of
conﬁdence intervals
supporting non-
inferiority
Proportion of
conﬁdence intervals
supporting
equivalence
80% 0.60 400 80.1% 60.5%
0.70 347 79.9% 59.5%
0.80 273 80.5% 60.8%
0.90 163 80.5% 60.9%
90% 0.60 520 89.9% 79.8%
0.70 455 89.7% 79.3%
0.80 360 90.4% 80.7%
0.90 210 90.0% 80.0%
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about 10% to 20% depending on study power.
8. Conclusion
Equivalence trials are preferred, and non-inferiority trials may
be considered if appropriately justiﬁed [1,2]. Prior to initiating an
equivalence or non-inferiority trial for the purpose of demon-
strating that the SBP has similar efﬁcacy and safety to the RBP,
a careful evaluation of all comparative data that have been gener-
ated between the SBP and the RBP should be performed to ensure
that similarity between the SBP and the RBP has been clearly
established. This is important, as the equivalence or non-inferiority
study marks the last step of the comparability exercise, and the
study should be initiated when there is unequivocal evidence that
the SBP can be considered similar to the RBP. It is also vital that the
protocol of the trial designed to demonstrate equivalence or non-
inferiority of the SBP to the RBP contains a clear statement that
this is the intention.
The choice of the RBP is critical. It should be a widely used
therapy whose efﬁcacy in the relevant indication has been clearly
established and quantiﬁed in well-designed and well-documented
placebo controlled trials. The choice of the equivalence or non-
inferiority margin must be clearly justiﬁed. Equivalence and non-
inferiority trials require different formulae for power and sample
size calculations, and the appropriate set of formulae should be
used in each setting. Factors which reduce the assay sensitivity of
a trial should be avoided or minimised, and the equivalence or non-
inferiority trial must be designed and conducted in the same
manner as the trial that established the efﬁcacy of the RBP to ensure
the constancy assumption. The totality of the data obtained from
the equivalence or non-inferiority trial will determine whether the
SBP can be considered clinically similar to the RBP.Conﬂict of interest
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